HOME >> BIOLOGY >> NEWS
Enzyme studies at Brookhaven Lab may lead to new antiviral agents

UPTON, NY -- Three new enzyme studies at the U.S. Department of Energy's Brookhaven National Laboratory have yielded a new strategy for blocking infection by human adenovirus. The findings, reported in the October, November, and December issues of the journal Biochemistry, have already been used to design novel antiviral drugs.

Adenoviruses cause a number of acute infections, including respiratory and gastrointestinal infections, and also conjunctivitis. In patients with compromised immune systems, such as those infected with human immunodeficiency virus (HIV), an opportunistic adenovirus infection is frequently deadly. "Our new antiviral drugs are expected not only to inhibit adenovirus, but might also be effective against other organisms that use the same enzyme -- including Chlamydia, one of the most prevalent sexually transmitted diseases, and Yersinia pestis, the organism that causes the black plague," said Walter Mangel, the lead scientist on the studies.

During infection, these viruses make an enzyme called a protease, which cleaves or degrades other proteins. The protease is used by the virus to complete the maturation of newly synthesized virus particles. To explain this process, Mangel uses the example of building a cathedral around internal scaffolding. Once the cathedral is in place, the last step is to remove the scaffolding. "Similarly," says Mangel, "adenovirus particles are built with scaffolding protein inside. Once the virus particle is formed, the protease becomes activated and cleaves the scaffolding to render the virus particle infectious."

The three recent Brookhaven studies reveal that the protease is initially synthesized in an inactive form. The inactive enzyme binds to the viral DNA to become partially activated.

"Such activation of a protease by DNA has never been seen before," Mangel said.

The partially activated enzyme then cleaves out a cofactor (a protein fragment), which binds to the protease to
'"/>

Contact: Karen McNulty Walsh
kmcnulty@bnl.gov
631-344-8350
DOE/Brookhaven National Laboratory
4-Dec-2001


Page: 1 2 3

Related biology news :

1. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
2. Enzyme activation appears key in helping internal clock tell night from day
3. Enzyme fully degrades mad cow disease prion
4. Enzyme revealed that is key to funguss ability to breach immune system
5. Enzyme discovery sheds light on causes of rare disease, cancer
6. Enzyme could overcome industrial bleaching waste problems
7. Enzyme controls good cholesterol
8. Enzyme discovery to benefit homeland security, industry
9. Enzyme could aid cancer fight
10. Enzyme once thought harmful to Alzheimers patients now appears key to future treatment
11. Enzyme mimetic reduces tissue damage in colitis animal study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2019)... ... July 18, 2019 , ... ... Meredith James, HT, PMP, to its executive team as Vice President of Operations. ... drug development. In her new role, Ms. James is responsible for ensuring on-time ...
(Date:7/17/2019)... ... 15, 2019 , ... RCH Solutions (RCH), a ... companies, announces the availability of new specialty advisory practice, a Public Cloud Managed ... emerging bio-pharma companies interested in achieving specific outcomes related to public Cloud adoption. ...
(Date:7/17/2019)... ... ... Imagine using a simple, portable test to detect cancer before malignant tissues ... South Dakota School of Mines & Technology researcher Congzhou Wang, Ph.D., these ideas are ... to monitor and prevent disease,” says Wang. , Wang, an assistant professor in ...
Breaking Biology News(10 mins):
(Date:7/26/2019)... ... July 25, 2019 , ... LeadingBiotech , an exclusive ... announces its Boston BD conference to be held on September 10, ... Boston , the event provides an opportunity for attendees to leverage insight from ...
(Date:7/17/2019)... , ... July 16, 2019 ... ... long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), ... this collaboration, AveXis, a Novartis company, will have dedicated manufacturing space at ...
(Date:7/2/2019)... ... July 02, 2019 , ... Leading Regenerative Veterinary Medicine company, ... Where Beasts Meet Biotech. The film focuses on regenerative veterinary medicine as a ... Pharm was recently included in the Brentwood and Pacific Palisades International Film ...
(Date:6/11/2019)... ... June 10, 2019 , ... Thought Technology Ltd is ... of Biofeedback Tech Ltd as its authorised distributor for the UK ... many therapeutic treatments and clinical assessment protocols to treat stress related disorders as ...
Breaking Biology Technology:
Cached News: